Uncategorized
Marketing authorization application filed in Europe for Durasert 3-year uveitis treatment
A marketing authorization application has been filed to the European Medicines Agency for the approval to market Durasert 3-year treatment for posterior segment uveitis, according to a pSivida press release.The treatment has seen its primary efficacy endpoints met in two phase 3 trials, reducing the recurrence of posterior segment uveitis in patients through 6 months.